MLSS

Business Context and Reporting Period

Company: Milestone Scientific Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Milestone Scientific develops and markets computer-controlled local anesthesia delivery systems (C-CLAD), primarily the STA Single Tooth Anesthesia Instrument and CompuDent, for the dental industry. The company is also pursuing strategic collaborations to adapt its CompuFlo technology for medical applications, including intra-articular and epidural drug delivery.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net product sales decreased by 5.3% ($136,590) compared to Q1 2010. This was driven primarily by a 36% drop in international handpiece sales due to a suspension of shipments to a major Chinese distributor pending regulatory approval.
• Profitability Shift: The company reported a net loss of $141,644 in Q1 2011, a reversal from a net income of $83,922 in Q1 2010. This swing was caused by lower gross profit dollars, increased selling and administrative expenses, and the absence of a one-time $61,916 tax credit sale recorded in 2010.
• Liquidity Deterioration: Cash and cash equivalents dropped significantly from $627,082 at year-end 2010 to $155,263 at March 31, 2011. The company moved from positive to negative working capital ($177,786 deficit) due to increased advances to contract manufacturers and accounts receivable tied up in the delayed China shipment.
• Expense Management: Selling, general, and administrative (SG&A) expenses increased by 5.4% due to higher travel costs for new sales directors and trade show expenses. Conversely, R&D expenses decreased by 50.6% ($44,746 reduction).

Outlook, Risks, and Contingencies

• Going Concern Warning: Management states that the company's recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern. The company may need to raise additional capital to fund operations and marketing efforts.
• China Regulatory Delay: A significant portion of the company's liquidity strain is attributed to the delay in obtaining regulatory approval in China. A major distributor has not received approval to sell the products, resulting in suspended shipments and a $624,000 reserve against accounts receivable from this customer.
• Joint Venture Progress: In March 2011, the company entered a new agreement with a PRC entity to establish a joint venture for medical applications of its technology. While an initial $250,000 contribution was made to a domestic R&D corporation, the PRC joint venture entity has not yet been established.
• Capital Requirements: The company does not believe it has sufficient cash reserves to meet all anticipated obligations for the next twelve months without additional revenue growth or capital raises. Failure to secure funding could force a curtailment of development and marketing activities.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $155,263 cash balance against the negative operating cash flow of $482,401 for the quarter.
• China Regulatory Status: Confirm the current status of the regulatory approval process in China, as this is the primary driver of the working capital deficit and revenue decline.
• Receivables Quality: Review the $624,000 allowance for doubtful accounts related to the Chinese distributor and the collectability of the remaining $273,160 long-term receivable.
• Capital Raising Plans: Assess management's specific plans and timeline for raising additional capital to address the "going concern" uncertainty.
• Joint Venture Funding: Monitor the establishment of the PRC joint venture and the receipt of the remaining $1.25 million in committed funding.